The IRE Resource Center is a major research library containing more than 23,250 investigative stories — both print and broadcast. These stories are searchable online or by contacting the Resource Center directly (573-882-3364 or rescntr@ire.org) where a researcher can help you pinpoint what you need. Browse or search the tipsheet section of our library below. Stories are not available for download but can be easily ordered by contacting the Resource Center:
Search results for "brand name drugs" ...
-
Bad Bargain
This article identifies several people who suffered consequences after switching from brand name drugs to generic ones. Furthermore, this article identifies loopholes that allow these generic drugs to reach the market. These generics, many of us believe are the same as the brand name ones, are actual substandard and un-equivalent.
Tags: Prescriptions; Drugs; Generic; Food and Drug Administration (FDA); Insurance companies; Brand Name; Doctors; Pharmacy; Pharmaceuticals
-
Divine Intervention: U.S. AIDS Policy
"The Center’s year-long investigation revealed how rigid rules and funding earmarks of President's Bush $15-billion initiative to fight HIV/AIDS abroad- the President's Emergency Plan for AIDS Relief- hinder effective HIV programming and frustrate countries struggling with the pandemic."
Tags: AIDS; HIV; South Africa; PEPFAR; Ethiopia; Haiti; condoms; education; generic drugs; brand name drugs
-
World's Cops Rec Up Strategies to nab cross-border car thieves.
Using techniques pioneered by drug traffickers and gun runners, illicit traders are plying cargo with brand names like Mercedes, Cadillac, and Lexus. Law enforcement and other experts say the worldwide trade in stolen cars and trucks is booming.
Tags: stolen cars; motor vehicles; smugglers
-
Generic Drugs: The Stalling Game
Consumer Reports investigates tactics used by brand-name drug manufacturers to delay the entry of generic drugs to the marketplace.
Tags: generic drugs; medicine; cost; Consumer Reports; business; insider information; FTC; trade; pharmaceuticals
-
The Stalling Game
Consumer Report looks at how "sweetheart deals and patent extensions keep lower-cost generic drugs from consumers." The story lists several approaches that both generic manufacturers and brand-name companies have used to gain and keep market exclusivity. These include: "sneaking patent-existing riders into complex and unrelated legislative procedures; paying chemical supply houses not to sell needed ingredients to rival drug manufacturers; paying competitors to stay out of the market; filing unfounded "citizen petitions" and patents to delay the marketing of a generic drug." The reporter points to specific examples of how pharmaceutical companies have taken advantage of loopholes in current law.
Tags: generic drugs; over-the-counter; Federal Trade Commission (FTC); drug patents; sales; research and development; FDA; health; medicine; Prescription Drug Competition Act
-
Child Play: Pharmaceutical Firms Win Big on Plan to Test Adult Drugs on Kids
The Wall Street Journal reports on "a drug-industry financial bonanza," resulting from the additional marketing exclusivity that drug makers have won by starting pediatric trials of adult medicine. The story examines the loopholes that allow the pharmaceuticals giants to protect themselves from generic competition half-a-year and earn extra revenues. The reporter reveals that "makers of generic drugs ... could lose $10.7 billion in sales over 20 years as a result of the six-month extension" for the patents of the brand-name drugs. The story looks at a number of flaws in the regulatory process.
Tags: Food and Drug Administration (FDA); Eli Lilly; Bristol-Myers; Merck; Schering-Plough; public health; children; juveniles; law
-
The Catalyst Behind Cipla's Offer of Cheap AIDS Drugs: Potent Mix of Motives
"Yusuf K. Hamied is a man with impressive humanitarian credentials. His pharmaceuticals company, Cipla Ltd. runs a free cancer-free hospital in India. And yet, even Dr. Hamied's friends say it wasn't simply compassion that drove the generic-drug pioneer to make his attention-grabbing offer last month to sell AIDS drugs at deep discounts.... One friend...says Dr. Hamied's offer was 'very much a business deal' designed to build Cipla's brand name outside India."
Tags: AIDS; Generic drugs; Pharmaceuticals
-
Drug Spies
Fortune Magazine reports that "piracy is the pharmaceutical industry's dirty little secret. fighting back has become its dirty little war, With the stakes this high, there are no rules, no conventions. But that doesn't mean there haven't been prisoners. The $300-billion-a-year pharmaceutical industry is mired in a hidden war ... It is a war fought from behind mountains of litigation, one that pits the leading multinationals against a growing army of scoundrels who are either counterfeiting medicines outright (a criminal offense in which specific drugs are copied down to the form, color, and name brand) or peddled "bioequivalent" generics that infringe brand-name patents (a civil offense, but just as painful financially for the patent holders.)"
Tags: Pharmaceuticals; espionage; Bayer; prison; piracy